Seach Medical 2025: Cash Stayed Strong, but 2026 Is Still a Proof Year

Getting to Know the Company

Seach Medical is no longer just a cannabis grower. It is a vertically integrated platform that now operates across several links in the chain: cultivation and propagation, in-house manufacturing, wholesale brands, import and export activity, and a network of 6 pharmacies. That is the right starting point for reading 2025. A reader who looks only at net profit or only at the dividend misses the point: the company has clearly built real operating flexibility, but it still has not proved that this flexibility translates into cleaner growth and higher returns across all the layers it bought and built.

What is working now is fairly clear. Gross margin before fair-value effects held at 30.9%, operating cash flow reached NIS 17.5 million, liquid resources rose to NIS 28.3 million, and the company entered 2026 with NIS 25 million of bank-credit lines, of which NIS 22 million was unused. That is not trivial in an industry where competition is intensifying, prices are under pressure, and some players are collapsing.

But the picture is still not clean. Revenue fell 8% to NIS 157.2 million, operating profit dropped to NIS 4.2 million, and profit attributable to shareholders was only NIS 1.5 million. On top of that, the company recorded an NIS 8.0 million goodwill impairment tied to three pharmacy units: Tifrachat, Even Hen, and Pharma 10. In other words, the layer that was supposed to bring Seach closer to the end customer and lock in a vertical advantage is also the layer that still has not generated returns strong enough to justify the value once carried on the balance sheet.

That is the core of the 2025 story. Seach proved resilience, not breakout. It looks stronger than many peers because it has a brand, broader control of the value chain, positive cash generation, and a relatively comfortable balance sheet. But it still has not shown that the full structure is creating a new earnings tier. That is why 2026 looks less like a harvest year and more like a proof year.

The company’s economic map in 2025 looks like this:

Events and Triggers

The first trigger: the dividend approved after the reporting date, NIS 0.18 per share and roughly NIS 6 million in aggregate, tells the market how the board wants the balance sheet to be read. It is a confidence signal about liquidity. But it also raises the bar. After a year in which profit attributable to shareholders was only NIS 1.5 million, a NIS 6 million dividend is not being paid out of clean annual earnings. It is being paid out of cash capacity. That means any weakness in 2026 will also be judged through capital-allocation discipline.

The second trigger: in March 2025 the group signed an additional distribution agreement with another distributor for a four-year term. That matters more than it looks at first glance, because the investor presentation says a major distributor experienced operational difficulties that affected the company as well, while the notes show that one manufacturer working with the group entered a stay-of-proceedings process. So Seach was not just expanding its distribution layer. It was actively reducing operating dependence on any single external node.

The third trigger: the anti-dumping investigation into Canadian imports did not end with an actual levy. For Seach this matters because the company imports raw material from abroad and also markets brands based on imported supply. The dismissal of the petition in December 2025 and the expiry of the appeal window in February 2026 remove, at least for now, one regulatory overhang that could have hurt margins and supply flexibility.

The fourth trigger: Shafa Kaan is expected to merge into Seach at the end of March 2026. This is not an event that changes the economics by itself, but it does continue the broader pattern of simplifying the structure and embedding the pharmacy layer more deeply into the group. The market will want to see whether that simplification improves execution, not just legal form.

The fifth trigger: the market backdrop itself remains crowded. The company estimates that Israel has about 135 thousand patients, roughly 350 to 400 licensed pharmacies, dozens of cultivation farms, and dozens of brands, while around 50 tons of medical cannabis were sold in 2025. That is not a market where a strong brand alone is enough. You need to keep proving operating advantage.

Efficiency, Profitability, and Competition

The key insight here is that the pressure in 2025 was mainly in growth, not in gross efficiency. Revenue fell to NIS 157.2 million because of changes in patient numbers, price pressure, and shifts in consumer preferences, but gross margin before fair-value effects barely moved and stayed at 30.9% versus 31.0% in 2024. That suggests the factory, the product mix, and the broader grip on the value chain really did absorb part of the market stress.

That matters, because without that layer 2025 could have looked much weaker. Cost of sales fell almost in line with revenue, while the company also cut selling and marketing expense by NIS 2.6 million and G&A by NIS 1.4 million. There is real operating discipline here. This is not a company carrying a fixed cost base unchanged into a softer market.

But that is not where the analysis should stop. The problem is that this efficiency still has not turned into clean shareholder earnings. Gross profit fell to NIS 46.8 million, operating profit to NIS 4.2 million, and in the fourth quarter the company posted an operating loss of NIS 7.6 million. Yes, part of that fourth-quarter weakness came from the NIS 8.0 million goodwill impairment and about NIS 2 million of one-off cost-of-sales items. But even after adjusting for that, the picture is still one of stability, not a business stepping into a new growth curve.

The mix tells the story well. Retail was almost flat: NIS 60.4 million versus NIS 61.7 million a year earlier. It was wholesale that weakened, dropping from NIS 110.0 million to NIS 96.8 million. That means the pharmacy layer helped stabilize revenue, but it did not compensate for the pressure in the wholesale market. Since the company does not disclose segment profitability between the two layers, it is hard to measure which one really creates the bulk of value. The pharmacy goodwill impairment is a strong hint that the answer is less comfortable than management would prefer.

There is also a competitive signal here. The company estimates that its share of wholesale market units sold in Israel ranges between 11% and 17%, and the presentation still frames Seach as a market leader. That sounds strong, but it does not mean it has full pricing power. The annual report itself says revenue fell partly because of lower prices. So the share is there, the brand is there, but the market is still competitive enough to drag down the topline.

Another point readers may miss sits in the production structure. Seach has operated its own factory since November 2023, and that clearly improved flexibility. But according to the report, only 25% to 35% of the cannabis it sells wholesale comes from self-grown output. The rest of the supply still comes from cooperation with outside farms and from imports. So Seach’s vertical integration is a real operating advantage, but it is not full supply independence.

Cash Flow, Debt, and Capital Structure

This is where the framing needs discipline. If you read 2025 through net profit, it looks like a weak year. If you read it through all-in cash flexibility, it looks much stronger. Both readings are valid, but they do not say the same thing.

On the full cash picture, the company generated NIS 17.5 million from operations. Inside that number, one important support item should not be ignored: receivables fell by NIS 8.3 million. That is a real working-capital improvement, and the company explicitly attributes it mainly to better payment terms. At the same time, inventory increased by NIS 3.1 million and payables fell by NIS 1.4 million. So the strong cash flow did not come only from operating earnings. It also came from better collection dynamics.

Now to the other side of the bridge. In 2025 Seach paid NIS 4.0 million of dividends, NIS 3.0 million of lease principal, NIS 1.35 million of interest, about NIS 0.2 million of loan repayments, and NIS 1.1 million of capex. Even after all that, cash and money-market funds rose from NIS 17.9 million to NIS 28.3 million. So at the liquidity level, the year was clearly positive.

But that is precisely the point that needs to be stated correctly. This is a cash-flexibility story, not a clean recurring-profit story. Anyone who looks at the NIS 28.3 million and concludes that the earnings question is solved is reading the year too generously. Profit attributable to shareholders was only NIS 1.5 million, and operating profit was NIS 4.2 million. Cash stayed strong, but the earnings engine still looks narrow.

From a formal debt perspective, the picture is relatively comfortable. Short-term bank credit and other short-term loans totaled about NIS 4.2 million, the company had NIS 25 million of total credit lines with NIS 22 million unused, and it met the financial covenants under both bank agreements. Lease obligations also declined, with undiscounted contractual lease cash flows falling from NIS 20.2 million to NIS 16.1 million.

The practical implication is that visible financial leverage is not the bottleneck here. The bottleneck sits elsewhere: in business friction inside the chain. A manufacturer providing services to the group owes roughly NIS 4.8 million while under a stay-of-proceedings process. A customer loan of NIS 2 million is only due at the end of June 2026. There is also the Telcan dispute, against which the company recorded a provision of about NIS 425 thousand. So when looking at Seach, counterparty risk matters more right now than bank debt.

Outlook and Forward Read

Before getting into 2026, four non-obvious takeaways need to be locked in:

1. The company enters 2026 from a position of liquidity strength, but not from clean earnings strength.
2. The factory and the broader grip on the chain helped protect margin, but they still have not put revenue back on a growth path.
3. The pharmacy network stabilizes sales, yet the impairment shows the retail layer is still not delivering the return implied by the original strategic promise.
4. The near-term risk is not a banking problem but an operating and commercial one, tied to manufacturers, distributors, and customer exposure.

That is why 2026 looks like a proof year. Not because the company is under immediate financial stress, but because it has already done the hard part of building the platform and now needs to prove that the platform actually creates a higher earnings tier.

The first target is revenue stabilization or renewed growth without margin erosion. The company says it will keep focusing on the Israeli market, deepen end-customer contact, expand in-house manufacturing, and continue exporting to additional countries. That direction makes sense. But the real question is different: will more production and stronger distribution increase revenue, or will they mainly help manage a market that is no longer expanding fast enough.

The second target is moving the pharmacy layer toward profitability. That is stated explicitly in the forward-looking section, so the 2025 impairment cannot be dismissed as just a technical accounting item. If management itself frames retail profitability as a forward target, it is effectively saying the job is still unfinished. That also means the impairment is not just noise. It is an operating signal.

The third target is deeper internalization of production through the factory. The company says it intends to increase activity so that most of its production will eventually be performed in its own plant. If that happens without hurting flexibility and without loading up inventory, it could become one of the genuine thesis changers. If it does not, the result may simply be a higher fixed-cost layer with only partial savings.

The fourth target is managing counterparty risk. In the current report Seach still looks like a company with solid cash and liquidity, which means this does not yet read like a balance-sheet problem. But this is exactly the stage where the market will watch whether the manufacturer debt, the customer loan, and the exposure to the grower in liquidation get resolved quietly or linger as a drag.

There is also a clear short-to-medium-term market read here. The first glance at the report may focus on the dividend, the cash, and the NIS 14.1 million adjusted EBITDA. That is too shallow. What will really determine the 2026 reading is whether the next few quarters show a combination of three things: stable sales, better pharmacy economics, and continued positive cash flow that does not rely mainly on shrinking receivables.

Risks

The first risk is competition. The company itself describes an Israeli market with hundreds of players, dozens of brands, roughly 350 to 400 pharmacies, and about 135 thousand patients. When a market like that is not growing fast enough, competition quickly becomes a price, brand, and channel battle.

The second risk is dependence on other players along the chain. Yes, Seach reduced some of that dependence through its own factory, pharmacy network, and a second distribution agreement. But the report also makes clear that the company still relies on outside farms, imports, and external manufacturers and distributors. In the case of the manufacturer that entered a stay-of-proceedings process, the exposure even has a number: about NIS 4.8 million.

The third risk is the quality of the pharmacy strategy itself. The goodwill impairment at Tifrachat, Even Hen, and Pharma 10 does not mean another impairment must recur every year. But it does mean the assumptions around sales growth, margin, or discount rate have not converged to a comfortable reality. If 2026 does not bring visible operating improvement in that layer, the vertical story will remain incomplete.

The fourth risk is regulation and import exposure. The company is exposed to both import and export activity, and it also highlights currency exposure, mainly to the US dollar and the Canadian dollar. The anti-dumping investigation on Canada did not end in a levy, but the process itself showed how quickly an international supply layer can turn into a regulatory issue.

The fifth risk is operational rather than demand-driven. The company says its existing insurance does not fully cover inventory, and that as of the reporting date it still had not obtained a cyber-event insurance policy. Those are not the headline issues of 2025, but they are a reminder that a business with physical inventory and a pharmacy network is not judged only through the income statement.

The sixth risk is low trading liquidity in the stock. The latest daily trading volume was only around NIS 33.5 thousand, and short interest is negligible. That means the market is not expressing active skepticism through short positioning, but it also means the active investor base is narrow and price discovery can stay slow.

Conclusions

Seach exits 2025 in better shape than the revenue headline alone suggests. It has cash flow, liquidity, customer dispersion, an active factory, and a distribution and retail layer that reduces dependence on a single outside chain. That is what supports the thesis today.

The main blocker is still elsewhere: growth has not returned, and the pharmacy economics are not yet proved. That is why the 2026 market read will not be driven by the existence of cash and dividends alone. It will be driven by whether the vertical structure starts producing better profit, not just better protection.

Current thesis in one line: Seach looks like one of the more resilient players in the sector, but 2026 will test whether that resilience can become an earnings tier rather than just a defensive cushion.

What changed versus the earlier read is fairly clear: in 2025 Seach showed that the full-chain model can hold cash generation and liquidity, but it also showed through the impairment that the pharmacy layer is still not a fully proven value creator.

The strongest counter-thesis is that this reading is too conservative: one can argue that the fourth quarter was distorted by the impairment and one-off costs, while the factory, distribution setup, and brand have already done enough to justify a more constructive read on 2026.

What could change the market interpretation over the short to medium term is a combination of two things: a return to revenue growth without gross-margin damage, and measurable improvement in pharmacy profitability. If that shows up, Seach will start to look more like a winning platform and less like a company simply surviving a hard market better than others.

Why does that matter? Because in Israeli medical cannabis, the difference between a company that manages pressure well and a company that turns its structure into incremental profit is the whole difference between a defensive story and a business story that is actually starting to open up.

Over the next 2 to 4 quarters, Seach needs to show three things: that revenue stops falling, that the pharmacy layer moves closer to profitability, and that the counterparty frictions in production and distribution remain contained. If one of those breaks down, the thesis stays limited.